The following table provides an overview of the latest patents of Elan Pharmaceuticals, Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP2645106Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic Agent1
EP1793855Jan 19, 2022Prevention And Treatment Of Synucleinopathic And Amyloidogenic Disease1
EP1991267Dec 20, 2017Methods Of Treating Inflammatory And Autoimmune Diseases With Natalizumab1